Patrick Orestes de Azevedo

Dr. Patrick Orestes de Azevedo

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 February 2023 in npj Vaccines
Verified
Journal Article
Open access
PDF file
PAPatrick Orestes de Azevedo
Patrick Orestes de Azevedo
NHNatália S. Hojo-Souza
Natália S. Hojo-Souza
LFLídia P. Faustino
Lídia P. Faustino
MFMarcílio J. Fumagalli
Marcílio J. Fumagalli
IHIsabella C. Hirako
Isabella C. Hirako
RGRicardo T. Gazzinelli
Ricardo T. Gazzinelli
The current COVID-19 vaccines protect against severe disease, but are not effective in controlling replication of the Variants of Concern (VOCs). Here, we used the existing pre-clinical models of severe and moderate COVID-19 to evaluate the efficacy of a Spike-based DNA vaccine (pCTV-WS) for protection against different VOCs. Immunization of transgenic (K18-hACE2) mice and hamsters induced significant levels of neutralizing antibodies (nAbs) to Wuhan and Delta isolates, but not to the Gamma and Omicron variants. Nevertheless, the pCTV-WS vaccine offered significant protection to all VOCs. Consistently, protection against lung pathology and viral load to Wuhan or Delta was mediated by nAbs, whereas in the absence of nAbs, T cells controlled viral replication, disease and lethality in mice infected with either the Gamma or Omicron variants. Hence, considering the conserved nature of CD4 and CD8 T cell epitopes, we corroborate the hypothesis that induction of effector T-cells should be a main goal for new vaccines against the emergent SARS-CoV-2 VOCs.

4 December 2021 in Viruses
Verified
Journal Article
Open access
PDF file
MFMarcilio Fumagalli
Marcilio Fumagalli
LCLuiza Antunes Castro-Jorge
Luiza Antunes Castro-Jorge
Thais Fernanda de Campos Fraga-SilvaThais Fernanda de Campos Fraga-Silva
Thais Fernanda de Campos Fraga-Silva
PAPatrick Orestes de Azevedo
Patrick Orestes de Azevedo
CCCarlos Fabiano Capato
Carlos Fabiano Capato
LFLuiz Tadeu Figueiredo
Luiz Tadeu Figueiredo
The persistent circulation of SARS-CoV-2 represents an ongoing global threat due to the emergence of new viral variants that can sometimes evade the immune system of previously exposed or vaccinated individuals. We conducted a follow-up study of adult individuals that had received an inactivated SARS-CoV-2 vaccine, evaluating antibody production and neutralizing activity over a period of 6 months. In addition, we performed mice immunization with inactivated SARS-CoV-2, and evaluated the immune response and pathological outcomes against Gamma and Zeta variant infection. Vaccinated individuals produced high levels of antibodies with robust neutralizing activity, which was significantly reduced against Gamma and Zeta variants. Production of IgG anti-S antibodies and neutralizing activity robustly reduced after 6 months of vaccination. Immunized mice demonstrated cellular response against Gamma and Zeta variants, and after viral infection, reduced viral loads, IL-6 expression, and histopathological outcome in the lungs. TNF levels were unchanged in immunized or not immunized mice after infection with the Gamma variant. Furthermore, serum neutralization activity rapidly increases after infection with the Gamma and Zeta variants. Our data suggest that immunization with inactivated WT SARS-CoV-2 induces a promptly responsive cross-reactive immunity response against the Gamma and Zeta variants, reducing COVID-19 pathological outcomes.

1 February 2022 in Viruses
Verified
Journal Article
Open access
PDF file
MFMarcilio Fumagalli
Marcilio Fumagalli
LCLuiza Antunes Castro-Jorge
Luiza Antunes Castro-Jorge
William SouzaWilliam Souza
William Souza
PAPatrick Orestes de Azevedo
Patrick Orestes de Azevedo
AHAlana Witt Hansen
Alana Witt Hansen
LFLuiz Tadeu Figueiredo
Luiz Tadeu Figueiredo
The emergence of new SARS-CoV-2 variants represents a constant threat to world public health. The SARS-CoV-2 Delta variant was identified in late 2020 in India; since then, it has spread to many other countries, replacing other predominant lineages and raising concerns about vaccination efficiency. We evaluated the sensitivity of the Delta variant to antibodies elicited by COVID-19 vaccinated (CoronaVac and ChAdOx1) and convalescent individuals previously infected by earlier lineages and by the Gamma variant. No reduction in the neutralizing efficacy of the Delta variant was observed when compared to B lineage and a reduced neutralization was observed for the Gamma variant. Our results indicate that neutralization of the Delta variant is not compromised in individuals vaccinated by CoronaVac or ChAdOx1; however, a reduction in neutralization efficacy is expected for individuals infected by the Gamma variant, highlighting the importance of continuous vaccination even for previously infected individuals.

1 October 2021 in Acta Tropica
Verified
Journal Article
Closed access
DSDenise da Silveira-Lemos
Denise da Silveira-Lemos
GAGlaucia Diniz Alessio
Glaucia Diniz Alessio
MBMaurício Azevedo Batista
Maurício Azevedo Batista
PAPatrick Orestes de Azevedo
Patrick Orestes de Azevedo
JRJoão Luís Reis-Cunha
João Luís Reis-Cunha
DBDaniella Castanheira Bartholomeu
Daniella Castanheira Bartholomeu

20 July 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
Marcos Gontijo SilvaMarcos Gontijo Silva
Marcos Gontijo Silva
NCNoé Mitterhofer Eiterer Ponce de Leon da Costa Costa
Noé Mitterhofer Eiterer Ponce de Leon da Costa Costa
RFRaphael Gomes Ferreira
Raphael Gomes Ferreira
PAPatrick Orestes de Azevedo
Patrick Orestes de Azevedo
HGHelierson Gomes
Helierson Gomes
ÉGÉrica Eugênio Lourenço Gontijo
Érica Eugênio Lourenço Gontijo
Background: To evaluate the sociodemographic and clinical profiles of pregnant women with positive IgM anti‑T. gondii in the eastern Brazilian Legal Amazon, during the period from 2018 to 2023. Methods: This was an indirect observational study through the retrospective analysis of 1,049 medical records from pregnant women attended in the Obstetrics service of Basic Health Units. The dependent variable was the presence of IgM antibodies, and the independent variables included age brackets, ethnicity, schooling, occupation, and clinical complaints. Data were analyzed using Epi‑Info 3.3.2 software. Risk factors and odds ratio (OR) with 95% CI were calculated. Results: From the 1,049 medical records analyzed, 52 (4.97%) presented IgM anti‑T. gondii antibodies. There was a significant correlation between IgM presence and age older than 30 years (OR 2.17; CI: 1.60–7.12), being employed (OR: 8.42; CI: 1.05–22.12), being married (OR: 3.02; CI: 1.43–9.32), and having less than eight years of schooling (OR: 3.04; CI: 1.24–11.56). Conclusions: The prevalence of IgM antibodies in the studied population was considered high, associated with low schooling, employment, and age over 30 years. The asymptomatic characteristic of acute infection is highlighted, reinforcing the need for effective prenatal screening.

10 September 2026 in Future Pharmacology
Verified
Journal Article
Open access
PDF file
AMAna Taynara Ferreira de Melo
Ana Taynara Ferreira de Melo
JMJoece Ferreira de Melo
Joece Ferreira de Melo
ESEzequiel Marcelino da Silva
Ezequiel Marcelino da Silva
Marcos Gontijo SilvaMarcos Gontijo Silva
Marcos Gontijo Silva
RFRaphael Gomes Ferreira
Raphael Gomes Ferreira
Raimundo Wagner de Souza AguiarRaimundo Wagner de Souza Aguiar
Raimundo Wagner de Souza Aguiar
Background/Objectives: Microbial exopolysaccharides (EPS) are complex biopolymers that mimic the native extracellular matrix and have emerged as promising biomaterials for tissue regeneration. Methods: This study aimed to evaluate the therapeutic potential of microbial EPS in the healing of cutaneous wounds through a systematic review and meta-analysis of in vivo experimental studies in rat models. Conducted in accordance with the PRISMA guidelines, a search of the Scopus, Embase, and ScienceDirect databases identified 2496 records. After rigorous screening, 17 rat studies were included in the quantitative synthesis, comprising 181 animals and 398 wounds (199 treated with EPS and 199 controls). Results: Treatment with EPS promoted a mean healing rate of 90.46% (range: 9.1% to 100%) on day 14, reflecting the heterogeneity of the included studies. The meta-analysis revealed an overall mean difference of 21.15% (95% CI: 17.89 to 24.42; p < 0.0001) in favor of EPS compared with the control group. Conclusions: These findings support the potential for translating EPS-based therapies from rodent models to human wounds, although the substantial heterogeneity of the evidence and the absence of clinical data indicate that controlled clinical trials remain essential to validate their application in humans.